RBC-transfusion dependency (RBC-TD) is an independent prognostic factor for poor overall survival (OS) in the WHO classification-based prognostic scoring system (WPSS) for MDS patients.
| I N T R O D U C T I O N
Myelodysplastic Syndromes (MDS) are heterogeneous clonal myeloid neoplasms characterised by cytopenia and morphological abnormalities in one or more lineages, and increased risk of transformation to acute myeloid leukemia (AML). 1 The survival of patients with MDS varies from near normal in indolent cases to <12 months in higher risk cases. [2] [3] [4] To evaluate the prognosis of MDS patients several prognostic scoring systems have been developed, including the widely used International Prognostic Scoring System (IPSS) 2 and WHO classificationbased prognostic scoring system (WPSS), 5 as well as the less commonly used MD Anderson Prognostic Scoring System (MPSS). 6 These prognostic models have advantages and limitations. 7, 8 Some limitations of RBC-transfusion dependency (RBC-TD) is an independent prognostic factor for poor survival in the WHO classification-based prognostic scoring system (WPSS), 5 and was adopted by the US Food and Drug Administration for approval of drugs for treatment of low risk MDS (e.g., lenalidomide in del(5q) MDS). 10 However, the WPSS did not include cytopenia, whereas the IPSS-R included three cut-offs of hemoglobin, which was thought to substitute for RBC-TD. 3 Thus, none of the published prognostic scoring systems integrates both cytopenia and RBC-TD. We aimed to test whether dynamic assessment of RBC-TD adds prognostic value to the IPSS-R, in addition to that offered by hemoglobin levels at diagnosis.
| M E T H O D S

| Patient selection
We analyzed MDS patients registered in the South Australian MDS registry (SA-MDS Registry; derivation dataset; n 5 295), and the D€ usseldorf registry, Heinrich-Heine-University Hospital, D€ usseldorf, Germany (validation dataset; n 5 113). As this study was planned to assess the prognostic impact of RBC-TD in addition to recently derived IPSS-R, inclusion criteria used for this study were aligned with the inclusion criteria of IPSS-R study. Inclusion criteria for this study were:
primary MDS not treated with disease-modifying therapy (i.e., hypomethylating agents, erythropoiesis-stimulating agents, lenalidomide, intensive chemotherapy, or hematopoietic stem cell transplantation), bone marrow (BM) blasts 30% and peripheral blasts 19%. RBC-TD was defined according to the WPSS classification as at least one unit of packed red cells transfused every 8 weeks for 4 months. 5 All other patients were considered transfusion-independent (RBC-TI). Institutional ethics committee approvals were obtained from the respective institutions and the procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000.
| Statistical analysis 2.2.1 | Derivation dataset (SA)
Landmark analyses of overall survival (OS) from 6, 12, and 24 months after diagnosis excluded individuals who had died before the landmark time point, the remaining patients were classified into two groups-RBC-TD noted at or before the landmark time point and RBC-TI at the landmark time point. The log-rank test was used to compare the groups. Cumulative incidences of AML transformation and death without prior transformation (non-leukaemic death) were also computed from each landmark time point using R and the cmprsk package. 11 The Wald test was used to compare the groups. These analyses were also repeated in the Low and Intermediate risk IPSS-R subgroups.
Univariate and multivariate Cox proportional hazards models for OS (excluding patients who died within 6 months of diagnosis) that used age at diagnosis, sex, IPSS-R component variables, or alternatively IPSS-R risk categories, and RBC-TD as a time-varying covariate (an indicator function with a step at the start date of TD) were fitted and the Akaike Information Criterion (AIC) 12, 13 was used to guide the selection of the best fitting model. 14 The prognostic index (PI) corresponding to the best fitting model was also the basis for a prognostic group (PG) factor with four levels-the cutpoints being determined by Cox's method. 15 Landmark analyses of OS from 6, 12, and 24 months after diagnosis were conducted to compare the patients in the PG's. 16 PG membership at each landmark was based on a recalculation of the PI at the landmark time point to take account of any changes in RBC-TI status.
| Validation dataset (Dusseldorf)
The PI, developed in the derivation dataset, was calculated for each individual in the validation dataset, excluding patients who died within 6 months of diagnosis, centred on a mean of zero, and the cut-off points established for the derived dataset were used to classify the patients in the validation dataset into the four prognostic groups. The associations of the calculated PI's and PG membership with OS were investigated by Cox proportional hazards regression and the log-rank test respectively. Landmark analyses of OS, in the validation dataset, from 6, 12, and 24 months after diagnosis were conducted to compare the patients in the PG's. PG membership at each landmark was based on a recalculation of the PI at the landmark time point to take account of any changes in RBC-TI status.
All analyses were conducted using the PHREG and LIFETEST procedures in SAS Version 9.4 unless otherwise stated. Median potential follow-up was estimated by reverse Kaplan-Meier.
| R E S U L T S
In the derivation dataset, the median age of the 295 primary MDS patients at the time of diagnosis was 75 (21-97) years comprising 66%
(n 5 196) males (Supporting Information Table S1 ). The estimated median potential follow-up time was 7.3 years. Our cohort was similar, in terms of the distribution of patients in risk groups and survival outcomes, to the cohorts in which the IPSS and IPSS-R were developed (Supporting Information Table S2 and Figure S1A ,B).
| Landmark analyses demonstrate poor prognosis of RBC-TD patients
During the study period 4324 RBC transfusion episodes were reported, 79% of which were given with a pre-transfusion Hb 90 g L
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. Only 6% RBC-transfusion episodes were given when the pre-transfusion Hb was 100 g L 21 (Supporting Information Figure S2A ). The Hb trigger for RBC-transfusion did not change significantly over 25 years (Supporting Information Figure S2B ). Furthermore, the Hb trigger for RBC-transfusion was not significantly different between age groups (Supporting Information Figure S2C ).
The IPSS-R risk group for each patient was calculated at the time of diagnosis and RBC-TD was continuously reassessed from diagnosis onwards. The prevalence of RBC-TD at diagnosis was 61/295 (20.7%), while the cumulative incidence of RBC-TD at any time during the study was 125/295 (42.4%). The cumulative incidence of RBC-TD was significantly higher in IPSS-R High and Very high risk groups compared to the Very Low risk group (P 5 0.0003; Supporting Information Figure S2D ).
The poor prognosis associated with RBC-TD was demonstrated in a series of landmark analyses. In the 6-month landmark analysis (n 5 255) the OS of RBC-TD patients was significantly inferior to that of RBC-TI patients (median OS 18 vs. 64 months; P < 0.0001; Figure   1A ). Similarly, landmark analysis at 12 months (n 5 224; median OS 24 vs. 71 months; P < 0.0001) and 24 months (n 5 165; median OS 40 vs. patients who became RBC-TD by 6, 12, and 24 months tended to be shorter than the OS of IPSS-R Intermediate risk RBC-TI patients ( Figure   2 and Supporting Information Figure S3 ), thus inclusion of RBC-TD "upstaged" some IPSS-R Low risk patients.
| Cumulative incidence of non-leukaemic death is significantly higher in RBC-TD compared to RBC-TI patients
In a series of landmark analyses the cumulative incidence of AML transformation, with death without prior transformation as the competing risk, was assessed. As shown in Figure 1D -F, the cumulative incidence of non-leukaemic death (P < 0.0001) was significantly higher in the RBC-TD group compared to the RBC-TI group at 6, 12, and 24-month landmark analyses. This was also demonstrated in a subgroup analysis of IPSS-R Low risk cases at all three landmark analyses ( Figure   2D -F) and only at the 6-month landmark analysis of the IPSS-R Intermediate risk group (Supporting Information Figure S3D -F). The cumulative rate of transformation to AML was significantly higher in those patients who became RBC-TD by 6 months (P 5 0.03), but not at later time points (Figure 1D-F) . Together these data show that RBC-TD is an independent prognostic factor for survival, primarily due to an increased rate of non-leukaemic deaths. The leading causes of non-leukaemic deaths were infection, bleeding and cardiovascular issues (Supporting Information Table S3 ).
3.3 | Multivariate Cox regression models confirm poor prognosis of RBC-TD status independent of IPSS-R, age, and sex
In each of the three best fitting models (with least AIC or minimum AIC difference; Supporting Information Table S4 ), RBC-TD was an independent adverse prognostic marker in addition to age, sex, and IPSS-R variables (models 38 and 44; P < 0.0001) or IPSS-R categories (model 23; P < 0.0001). In the best fit model (model 38 in Table 1 ) the IPSS-R Tables S4 and S6 ). Importantly, when the model included RBC-TD as a time-dependent covariate and Hb at diagnosis, either as a continuous or categorical (according to IPSS-R cut-off) variable, RBC-TD was an independent adverse prognostic factor, but not Hb (models 38 and 44
in Table 1, Supporting Information Tables S4,5 ).
In a Cox regression model (model number 38 in Supporting Information Table S4 ) RBC-TD as a time-varying covariate (HR 5.28, P < 0.0001), older age (HR 1.08 with each year, P 5 0.0001), male sex (HR 1.97, P 5 0.0002), IPSS-R poor risk cytogenetic groups (P 5 0.03),
higher BM-blast percentage (HR 1.09, P < 0.001) and lower neutrophil count (HR 1.09; P 5 0.0006) were each independent prognostic factors for OS (Table 1) . Thus, RBC-TD as a time-dependent covariate is a more powerful prognostic marker than Hb at diagnosis.
| Validation of prognostic index in D€ usseldorf cohort
The South Australian dataset of 261 patients was used to derive a PI for OS (34/295 patients died within 6 months of diagnosis and were excluded from this analysis). The cut-off points determined by the Cox regression model for RBC-TD status as a time-varying covariate, IPSS-R variables, age, and sex of patients were used to derive a PI. The PI classified patients into four prognostic groups with, as expected, a significant difference in OS between the groups (P < 0.001; Supporting
Information Tables S7 and S8 ).
Landmark analyses with time varying prognostic groups were conducted separately in the derivation dataset at 6, 12, and 24 month landmarks. In the derivation dataset OS was, not unexpectedly, significantly different between the four prognostic groups, PG1, PG2, PG3, and PG4, in landmark analyses at 6 months (median OS: not reached vs. 94 vs. 33 vs. 14 months; P < 0.001), 12 months (median OS: not reached vs. 92 vs. 38 vs. 18 months; P < 0.001), and 24-months (median OS: not reached vs. 95 vs. 47 vs. 29 months; P < 0.001; Figure   3A -C and Supporting Information Table S8 ).
In the D€ usseldorf validation cohort 106 patients were analysed (7/ 113 patients died within 6 months of diagnosis and were excluded from further analysis). with unfavorable cytogenetic risk (7.2% vs. 18%; Supporting Information Table S1 ).
Cox regression of OS in the validation dataset using the PI developed in the derivation dataset resulted in a slope coefficient of 0.663 (SE 0.118) and showed significant OS differences between the four prognostic groups (P < 0.001), and a significantly higher risk of death in groups 3 (P 5 0.032) and 4 (P 5 0.007) relative to group 1 (Supporting Information Tables S7 and S8 ). Serial landmark analyses of the validation cohort also showed survival difference between the prognostic groups. In the 6-month landmark analysis, OS was significantly inferior in PG3 and PG4 compared to PG1 and PG2 (P < 0.03; Figure 3D ; Supporting Information Table S8 ). In the 12-month landmark analysis, OS was significantly inferior in PG3 and PG4 compared to PG2 (P 5 0.004 and P < 0.001, respectively; Figure 3E ; Supporting Information Table   S8 ) and in the 24-month landmark analysis, OS was significantly different between PG4 vs. PG2 (P 5 0.011; Figure 3F ; Supporting Information Table S7 ) but not between other prognostic groups (Supporting Information Table S8 ).
| DISCUSSION
Although RBC-TD has been shown to be an independent prognostic factor for inferior OS 5,17,18 it was not included in the IPSS-R. 3 Investigators of the IPSS-R suggested that the inclusion of three Hb categories at diagnosis would substitute for RBC-TD. 3 However, RBC-TD information was available in only 42% (2933/7012) of patients analysed in their IPSS-R derivation cohort, which most probably limited their analysis. 3 More importantly, RBC-TD status is dynamic and changes during the disease course. The Hb level at diagnosis cannot accurately reflect changes during follow-up. Multivariate analysis by
Cox proportional hazards regression and serial landmark analysis of the SA-MDS registry clearly demonstrates that the development of RBC-TD at any time during the disease course is associated with inferior OS, independent of IPSS-R variables/categories, age, and sex of patients. Importantly, the inclusion of RBC-TD "up-staged" some IPSS-R Low risk patients, which has therapeutic implications such as consideration for disease modifying therapy and/or allogeneic stem cell transplantation in suitable patients. We found that the inferior OS of RBC-TD patients were predominantly due to a higher rate of non-leukaemic deaths compared to RBC-TI patients. In our cohort the AML transformation rate was significantly higher in RBC-TD patients (P 5 0.03) only at 6-month landmark analysis, and not at other time points. Malcovati et al. also showed that non-leukaemic death was significantly higher in RBC-TD patients, most probably due to significantly higher rates of cardiac disease and cardiac death in RBC-TD patients compared to RBC-TI patients.
17
A prognostic index derived using cut-off points for each variable that was independently associated with survival in the Cox proportional regression model divided patients into four groups with different OS. When the PI was applied to the validation cohort the slope coefficient of the model was 0.663 (SE 0.118), which was significantly different from zero (P < 0.001) but was <1.0 (the slope coefficient of an ideal model). This difference in slope could be due to the relatively small number of patients, or could reflect differences in the prevalence of RBC-TD at diagnosis, age and number of patients with IPSS-R poor risk and very poor cytogenetic risk between the two groups. Despite these differences between the two cohorts, prognostic groups defined using cut-off points determined in the derivation dataset were associated with difference in OS in the validation cohort. In particular, patients in PG3 and PG4 had a significantly higher risk of death than patients in PG1 (P < 0.05). These analyses demonstrate that RBC-TD as a time-dependent covariate is a poor prognostic factor for OS independent of IPSS-R variables, age, and
sex.
An argument against the inclusion of RBC-TD as a prognostic factor is that it may be too subjective, since the trigger for RBC-transfusion varies between countries and depends upon patient symptoms and co-morbidities. 19 To this end, pioneering work by 17 Hence, RBC-TD was replaced with these pre-transfusion dependency Hb thresholds in the revised WPSS. An important difference between the assessment of anemia severity in the IPSS-R and revised WPSS studies was that the WPSS group monitored variation in Hb during the time course until the onset of RBC requirements, whereas the IPSS-R relies upon a single measurement of Hb at diagnosis. 17 Thus, the WPSS model is dynamic and reflects changes in the patients' status during follow-up.
In line with the Pavia data, in our study 79% of RBC-transfusions were given when the pre-transfusion Hb was 90 g L
21
. Importantly, in our study hemoglobin trigger for RBC-transfusion did not change significantly over 25 years. Together these analyses suggest that dynamic assessment of RBC-TD and pre-transfusion Hb provide similar prognostic information.
In summary, this is the first report demonstrating that inclusion of RBC-TD further refines the IPSS-R prognostic scoring system and upstages some lower risk patients. Decisions regarding disease-modifying treatment in MDS, including hypomethylating agents and allogeneic stem cell transplantation, are typically based on risk assessment. Therefore, the accurate, dynamic assessment of disease risk during follow-up can help to ensure that patients receive the most appropriate treatment at the appropriate time.
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